135 completed, 95 recruiting, 42 unknown, 32 not yet recruiting. 87 Phase 3, 64 Phase 2, 52 Not applicable, 46 Phase 1, 12 Early Phase 1.
Follow Neuromuscular Junction Diseases: new trials by email Literature Review of Neuromuscular Junction Diseases trials Research Report on Neuromuscular Junction Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG Myasthenia Gravis Generalized | Not yet recruiting | BioSensics | 25 | 2027-03-15 | 2026-10-13 | |
| Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG) HN2301 injection - Generalized Myasthenia Gravis | Phase 1 | Not yet recruiting | Shenzhen MagicRNA Biotechnology Co., Ltd | 6 | 2026-12-31 | 2026-08-12 |
| A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG) Ublituximab, Placebo - Myasthenia Gravis | Phase 2 | Recruiting | TG Therapeutics, Inc. | 120 | 2026-10-01 | 2026-09-22 |
| Evaluating the Safety and Effects of AMP-101 in People With DOK7 Congenital Myasthenia Syndrome AMP-101 - Congenital Myasthenia Syndrome | Phase 1 | Not yet recruiting | Amplo Biotechnology | 4 | 2026-10-01 | 2026-09-21 |
| Incidence and Predictors of Early Clinical Relapse Within Six Months After Thymectomy in Patients With Myasthenia Gravis Myasthenia Gravis, Thymoma | Not yet recruiting | Assiut University | 30 | 2026-10-01 | 2026-10-01 | |
| A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis Rozanolixizumab - Ocular Myasthenia Gravis | Phase 3 | Recruiting | UCB Biopharma SRL | 100 | 2026-09-16 | 2026-10-08 |
| Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis Myasthenia Gravis (MG), Myasthenia Gravis Associated With Thymoma | Not yet recruiting | IRCCS San Raffaele | 40 | 2026-09-15 | 2026-05-06 | |
| An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis EA5 - Generalized Myasthenia Gravis (gMG) | Phase 1 | Not yet recruiting | Shanghai Lanyi Therapeutics Co., Ltd. | 18 | 2026-09-15 | 2026-09-14 |
| A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS) Adimanebart IV, Placebo IV - Congenital Myasthenic Syndrome, CMS | Phase 3 | Not yet recruiting | argenx | 105 | 2026-09-01 | 2026-10-19 |
| A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis SHR-2173 injection, Placebo - Generalized Myasthenia Gravis | Phase 2 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 60 | 2026-08-28 | 2026-10-22 |
| Feasibility of Remote Monitoring of Patients With Myasthenia Gravis Myasthenia Gravis (MG) | Recruiting | George Washington University | 18 | 2026-08-19 | 2026-10-05 | |
| Sexual and Urinary Dysfunctions in Generalized Myasthenia No intervetion - Myasthenia Gravis (MG) | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 150 | 2026-07-30 | 2026-07-01 | |
| Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) Ravulizumab - Generalized Myasthenia Gravis, gMG | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 20 | 2026-07-27 | 2026-10-21 |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) Inebilizumab - Generalized Myasthenia Gravis | Phase 2 | Recruiting | Amgen | 15 | 2026-07-21 | 2026-10-05 |
| ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS - AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG) | Phase 2 | Recruiting | argenx | 40 | 2026-07-10 | 2026-10-16 |
| Universal STAR-T Cell Injection in Generalized Myasthenia Gravis Universal STAR-T Cell - Generalized Myasthenia Gravis | Phase 1 | Not yet recruiting | Daishi Tian | 10 | 2026-07-06 | 2026-07-20 |
| A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells Autologous 2nd generation - Multiple Sclerosis (MS), Myasthenia Gravis (MG) | Phase 1 | Not yet recruiting | The Affiliated Hospital of Qingdao University | 18 | 2026-07-01 | 2026-06-30 |
| A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE) Claseprubart, Placebo - Myasthenia Gravis, Generalized | Phase 3 | Recruiting | Dianthus Therapeutics | 195 | 2026-06-29 | 2026-09-25 |
| Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab) Patients diagnosed with generalized myasthenia gravis and treated with Rozanolixizumab - Generalized Myasthenia Gravis | Recruiting | Centre Hospitalier Universitaire de Nice | 50 | 2026-06-15 | 2026-09-01 | |
| PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis Myasthenia Gravis Generalized | Recruiting | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 40 | 2026-06-04 | 2026-07-21 |
Showing 20 of 372. Sign in to see all of them.
Myasthenia Gravis (319) · Multiple Sclerosis (26) · Lambert-Eaton Myasthenic Syndrome (22) · Autoimmune Diseases (19) · Botulism (19) · Myasthenic Syndromes, Congenital (19) · Autoimmune Diseases of the Nervous System (17) · Neuromyelitis Optica (17) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (15) · Neuromuscular Diseases (12) · Guillain-Barre Syndrome (11) · Thymoma (10) · Fatigue (9) · Lupus Erythematosus, Systemic (8) · Myositis (8)
Nervous System Diseases (367) · Neuromuscular Diseases (360) · Neurodegenerative Diseases (337) · Neoplasms by Site (335) · Immune System Diseases (334) · Nervous System Neoplasms (334) · Paraneoplastic Syndromes (334) · Paraneoplastic Syndromes, Nervous System (334) · Neoplasms (333) · Autoimmune Diseases of the Nervous System (320) · Autoimmune Diseases (318) · Pathological Conditions, Signs and Symptoms (63) · Pathologic Processes (48) · Disease Attributes (42)
Amifampridine (18) · rozanolixizumab (11) · efgartigimod alfa (10) · Cyclophosphamide (8) · Prednisone (8) · zilucoplan (8) · Pyridostigmine Bromide (7) · Rituximab (7) · ravulizumab (7) · Mycophenolic Acid (6) · Tacrolimus (6) · fludarabine (6) · telitacicept (6) · Immunoglobulins, Intravenous (5) · eculizumab (5)
argenx (20) · Alexion Pharmaceuticals, Inc. (16) · UCB Biopharma SRL (14) · Catalyst Pharmaceuticals, Inc. (6) · Centre Hospitalier Universitaire de Nice (5) · Charite University, Berlin, Germany (5) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (5) · Huashan Hospital (5) · Leiden University Medical Center (5) · Tang-Du Hospital (5) · Tongji Hospital (5) · Assistance Publique - Hôpitaux de Paris (4) · Assiut University (4) · Da, Yuwei, M.D. (4) · Novartis Pharmaceuticals (4)
United States (172) · China (87) · Italy (66) · Canada (60) · Germany (57) · France (56) · Poland (54) · Spain (52) · Japan (42) · United Kingdom (41) · Belgium (34) · Netherlands (26) · Denmark (25) · Taiwan (23) · Serbia (22)
Andreas Meisel, Prof. Dr. med. (3) · Raffaele Iorio (3) · Antonio Guglietta, MD (2) · Chongbo Zhao (2) · Daishi Tian (2) · David Richman, MD (2) · Donald Sanders, MD (2) · Gil Wolfe, MD (2) · Jan LS Thomsen, MD (2)
PMID 37059507, PMID 42388397, PMID 30905021, PMID 32189108, PMID 32426038, PMID 32700461, PMID 33219142, PMID 33229455, PMID 33329303, PMID 34146511, PMID 34590717, PMID 35350948, PMID 37059508, PMID 38099334, PMID 38400914, PMID 39068745, PMID 39314260, PMID 40105996, PMID 40504283, PMID 42855714, PMID 10227640, PMID 10891897, PMID 11339776, PMID 11383846, PMID 15705045, PMID 16267188, PMID 16849828, PMID 16900450, PMID 17051488, PMID 17264722, PMID 18173374, PMID 18567886, PMID 18675464, PMID 18946293, PMID 197596, PMID 20117014, PMID 20375901, PMID 20683334, PMID 21314428, PMID 21419697, PMID 21670440, PMID 21784757, PMID 22003934, PMID 22047648, PMID 22215056, PMID 23235588, PMID 23278584, PMID 23512355, PMID 23568718, PMID 23599531
2023 (12), 2025 (10), 2018 (5), 2016 (4), 2019 (3), U54NS115054 (2), 1RC3NS070670-01 (1), 2015 (1), 2017 (1), R01EY029437 (1), R44NS122672 (1), U01NS042685 (1), U01NS077179 (1), U01NS077352 (1), U01NS084495 (1)